News | December 17, 2006

FDA Says Yes to Stroke Device Study

The FDA has given CoAxia Inc. approval to move forward on a safety and feasibility study for the NeuroFlo perfusion augmentation therapy in ischemic stroke patients who present for treatment as late as 24 hours after stroke onset. Perhaps the first interventional device trial approved for this patient population, the study will enroll up to 25 patients and the results will determine future expansion to a pivotal study in late presenting stroke patients.

"This study represents another important step in applying medical devices to the treatment of acute stroke,” said Souvik Sen, M.D., director of the Stroke Service at the University of North Carolina and a co-author of the study. “There are no treatments currently approved to treat stroke patients in this eight- to 24-hour time window after symptom onset. If NeuroFlo can safely treat the large number of patients who present in this time window, it will have a major impact in stroke treatment."

The SafeFlo24 trial will evaluate the safety of the NeuroFlo perfusion augmentation catheter in stroke patients presenting for treatment between eight and 24 hours after last known to be normal. The study’s other co-authors are Lee Schwamm, M.D. from Massachusetts General Hospital, Maxim Hammer, M.D. from University of Pittsburgh Medical Center and David Liebeskind, M.D. from UCLA Medical Center. In addition to these four centers, the University of Rochester, New York, the University of Alberta, Edmonton and the University of Calgary, Calgary, will participate in the study. CoAxia expects patient enrollment to begin in the first quarter of 2007.

For more information visit www.coaxia.com

Related Content

MaxQ AI Launches Accipio Ax Slice-Level Intracranial Hemorrhage Detection
Technology | Stroke | May 21, 2019
Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that Accipio Ax will begin shipping in August...
Brain images that have been pre-reviewed by the Viz.AI artificial intelligence software to identify a stroke. The software automatically sends and alert to the attending physician's smartphone with links to the imaging for a final human assessment to help speed the time to diagnosis and treatment. Depending on the type of stroke, quick action is needed to either activate the neuro-interventional lab or to administer tPA.

Brain images that have been pre-reviewed by the Viz.AI artificial intelligence software to identify a stroke. The software automatically sends and alert to the attending physician's smartphone with links to the imaging for a final human assessment to help speed the time to diagnosis and treatment. Depending on the type of stroke, quick action is needed to either activate the neuro-interventional lab or to administer tPA. Photo by Dave Fornell.

Feature | Stroke | May 17, 2019 | Inga Shugalo
With its increasing role in medical imaging, ...
Videos | Stroke | May 16, 2019
This is an example of a carotid artery reporting module from Change Healthcare at...
 UTHealth Research Finds Telemedicine Stroke Patients Receive Consistent Care 24/7
News | Stroke | April 24, 2019
Stroke patients examined remotely by a teleneurologist were treated as quickly and effectively after hours as during...
New Stroke Training Model Improves Access to Life-Saving Care
News | Stroke | March 27, 2019
Training interventional radiologists to perform endovascular thrombectomies results in positive outcomes for patients...
Gregory W. Albers, M.D., Receives Distinguished Clinical Research Achievement Award for Stroke Research
News | Stroke | March 19, 2019
iSchemaView announced the company’s co-founder Gregory Albers, M.D., has received the Distinguished Clinical Research...
Corindus Seeking Neurovascular Intervention Clearance for CorPath GRX Vascular Robotic System
News | Stroke | February 15, 2019
Corindus Vascular Robotics Inc. is seeking premarket clearance from the U.S. Food and Drug Administration (FDA) to use...
NeuroLogica and MaxQ AI Announce Distribution Agreement
News | Stroke | November 30, 2018
Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement...
Medication Alone May Not Eliminate Stroke Risk in Carotid Atherosclerotic Stenosis Patients
News | Stroke | October 31, 2018
Recent statin and medication advances have led some researchers to suggest surgical treatments for carotid stenosis...
Overlay Init